These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12951129)

  • 1. Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
    Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Webb TR; Gu J; Xie YF; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3375-9. PubMed ID: 12951129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.
    Takeda K; Terauchi T; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4756-61. PubMed ID: 22683343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists.
    Nakazato A; Kumagai T; Okubo T; Tanaka H; Chaki S; Okuyama S; Tomisawa K
    Bioorg Med Chem; 2000 May; 8(5):1183-93. PubMed ID: 10882028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.
    Ahuja VT; Hartz RA; Molski TF; Mattson GK; Lentz KA; Grace JE; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2016 May; 26(9):2184-7. PubMed ID: 27020524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
    Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
    Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
    Primus RJ; Yevich E; Baltazar C; Gallager DW
    Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor.
    Hoare SR; Brown BT; Santos MA; Malany S; Betz SF; Grigoriadis DE
    Biochem Pharmacol; 2006 Jul; 72(2):244-55. PubMed ID: 16750175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
    Yuan J; Gulianello M; De Lombaert S; Brodbeck R; Kieltyka A; Hodgetts KJ
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2133-6. PubMed ID: 12127521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
    Mochizuki M; Kori M; Kobayashi K; Yano T; Sako Y; Tanaka M; Kanzaki N; Gyorkos AC; Corrette CP; Cho SY; Pratt SA; Aso K
    J Med Chem; 2016 Mar; 59(6):2551-66. PubMed ID: 26901666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
    Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.